Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative S (Q69225952)
Jump to navigation
Jump to search
scientific article published on 01 September 1989
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative S |
scientific article published on 01 September 1989 |
Statements
Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. European Co-operative Study Groups for rt-PA (English)
A E Arnold
R W Brower
D Collen
G A van Es
J Lubsen
M L Simoons
1 September 1989